Search
forLearn
5 / 801 resultslearn dl-alpha-tocopherol
learn acetyl methionine
learn phenoxyethanol
learn copper bisglycinate
Research
5 / 186 results
research Acute And Sub Chronic Toxicity Of Tridax Procumbens In Experimental Animals
High doses of Tridax procumbens extract can be toxic, affecting liver and kidneys.
research Systemic subchronic toxicity and comparison of four selenium nutritional supplements by 90-day oral exposure in Sprague-Dawley rats
High doses of some selenium supplements caused liver and reproductive harm in rats.
research Selenium Toxicity in Domestic Animals
Selenium can be toxic to animals, causing serious health issues, especially in horses.
research Subchronic study of sperm morphology, genotoxic and mutagenic effect of Lepidium sativum seeds aqueous extract in vivo
High doses of Lepidium sativum seed extract are toxic and should be used with caution.
research Acute and 30-day oral toxicity studies of a novel coccidiostat – ethanamizuril
Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
Community Join
5 / 1000+ resultscommunity Proof that finasteride messes with neurosteroids
Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.